Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.
Naomi B. Haas, MD, director of the kidney and prostate cancer program at Penn Medicine and professor of medicine at the Hospital of the University of Pennsylvania, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma (RCC).
According to Haas, the 3 approved frontline tyrosine kinase inhibitor/immune checkpoint inhibitor combinations were superior to sunitinib (Sutent) in favorable-risk patients but none of the 3 stood out as the best option in terms of patient outcomes. The choice of regimen can come down to other factors such as the different adverse event (AE) profiles and the patients’ ability to tolerate therapy. Additionally, she says she might use cabozantinib (Cabometyx) plus nivolumab (Opdivo) in a patient with bone metastases since it has activity against the MET pathway, which tends to have better outcomes for bone metastases.
Cabozantinib plus nivolumab or lenvatinib (Lenvima) plus pembrolizumab (Keytruda) could also be more appropriate than axitinib (Inlyta) plus pembrolizumab in patients who have high disease burden since these regimens were shown in trials to be better at providing rapid and deep responses.
TRANSCRIPTION:
0:08 | The cabozantinib/nivolumab, the axitinib/pembrolizumab and the lenvatinib/pembrolizumab patients all did well with favorable-risk disease but compared [with] a single-agent tyrosine kinase inhibitors such as sunitinib, which was the comparator arm, there wasn't a huge difference in how they did. Some of it is tailored to [AEs]. For example, if a patient develops bony metastases, and they're in the favorable-risk category, I might use cabozantinib/nivolumab a little bit more often than lenvatinib/pembrolizumab or axitinib/pembrolizumab, just based on the MET activity that is seen in cabozantinib, and how MET mutations may work a little bit better in patients with bone metastases, or MET-directed therapy, I should say.
1:16 | If they have a very high burden of disease, and I need shrinkage and I need shrinkage quickly, I would use either nivolumab and cabozantinib or I would use lenvatinib with pembrolizumab because those 2 [regimens] had a pretty decent depth of response and did well in those categories.
RELATIVITY-047 Vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy
October 10th 2024During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Functional High Risk and Bridging in Multiple Myeloma Considered With CAR T Cells
October 9th 2024Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with relapsed/refractory multiple myeloma and functional high risk, bridging to cilta-cel, and time to treatment in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More